title: A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
abstract: OBJECTIVE
  To determine the maximum tolerated dose and the dose-limiting toxicity of capecitabine with standard radiotherapy (RT) as adjuvant treatment in patients with rectal cancer.
  
  
  METHODS
  Patients with Stage II/III rectal cancer after surgery were eligible. Total RT dose was delivered as DT 50 Gy in fractions of 2.0 Gy/day for 5 weeks to the pelvic area. Capecitabine was administered concurrently with RT in escalating doses, twice daily with a 12-h interval, for two cycles of 14 days separated by a 7-day rest. Dose-limiting toxicity included Grade 3 or Grade 4 hematologic and nonhematologic toxicity.
  
  
  RESULTS
  Twenty-four patients were enrolled at the following dose levels: 1,000 (3 patients), 1,200 (3 patients), 1,400 (3 patients), 1,500 (3 patients), 1,600 (6 patients), and 1,700 mg/m2/day (6 patients). Dose-limiting toxicity was observed in 1 patient at 1,600 mg/m2/day (Grade 3 diarrhea) and in 2 patients at 1,700 mg/m2/day (1 patient had Grade 3 and 1 Grade 4 diarrhea).
  
  
  CONCLUSIONS
  The maximum tolerated dose (MTD) of capecitabine given concurrently with RT was 1,600 mg/m2, daily from the 1st to the 14th day, with a 7-day rest, for two cycles.
authors.affiliation: Department of Radiation Oncology, Cancer Hospital/Institute, Peking Union Medical College, Peking, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Jin
authors.forename: Ye-Xiong
authors.initials: YX
authors.lastname: Li
authors.forename: Yue-Ping
authors.initials: YP
authors.lastname: Liu
authors.forename: Wei-Hu
authors.initials: WH
authors.lastname: Wang
authors.forename: Yong-Wen
authors.initials: YW
authors.lastname: Song
authors.forename: Tao
authors.initials: T
authors.lastname: Li
authors.forename: Ning
authors.initials: N
authors.lastname: Li
authors.forename: Zi-Hao
authors.initials: ZH
authors.lastname: Yu
authors.forename: Xin-Fan
authors.initials: XF
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D003967:Diarrhea / Q000209:etiology; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil